HIPEC-AS for stomach cancer that has spread to the belly lining
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests a treatment called HIPEC-AS for stomach or food-pipe-junction cancer that has spread only to the peritoneum (the belly lining). It aims to see whether adding HIPEC-AS can improve cancer control for people who have not had prior cancer medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75
- Your main cancer is stomach or esophagogastric-junction adenocarcinoma
- The tumor is in the stomach or near the junction with the esophagus
- Your cancer has spread to the belly lining, and there are no other distant metastases
- You have not had chemotherapy, radiation, targeted therapy, or immunotherapy yet
- Your blood counts, liver, kidneys, and blood clotting tests are within required ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests a treatment called HIPEC done during/around surgery after chemotherapy for advanced stomach (gastric) cancer. It may help patients live longer or have fewer cancer-related problems after the operation.
This trial tests a combination of heated chemotherapy placed directly in the abdomen (HIPEC), chemotherapy given through a vein and the abdominal cavity (NIPS), and an immunotherapy drug (tislelizumab) for people with stomach cancer that has spread to the lining of the abdomen. The goal is to see if this approach can shrink the cancer enough to allow for surgery.
This Phase 2 trial studies a combination treatment for stomach (or stomach-to-esophagus) cancer that has spread to the belly lining. It tests whether adding the immunotherapy drug sintilimab to a procedure called HIPEC can improve outcomes for people who have not had prior treatment.
This trial tests a special type of chemotherapy that is heated and delivered directly into the belly during surgery (called HIPEC). It uses two drugs, cisplatin and paclitaxel, and is for people with stomach cancer who are at high risk of the cancer returning in the lining of the belly.
This Phase 3 trial studies whether adding a heated chemotherapy procedure during surgery (HIPEC) before the main cancer treatment can lower the chance that stomach cancer returns in the belly. It is for people with advanced stomach cancer who are at higher risk of cancer coming back in the peritoneum (the lining of the abdomen).
Hear when a new Stomach Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.